Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.51 |
| ▸ | F10 | P00742 | 3/20 | 0.50 |
| ▸ | PPARG | P37231 | 10/20 | 0.49 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.46 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.46 |
| ▸ | ICMT | O60725 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL974474 | 0.90 | CCR2 (0.69) | CCR2F10PPARG | |
| SCHEMBL926357 | 0.88 | F10 (0.61) | CCR2PLA2G10F10 | |
| SCHEMBL3979074 | 0.84 | F10 (0.52) | CCR2F10PPARG | |
| SCHEMBL3647083 | 0.83 | PLA2G10 (0.71) | CCR2PLA2G10F10PPARG | |
| SCHEMBL30425654 | 0.82 | PPARG (0.68) | CCR2PLA2G10F10PPARG | |
| SCHEMBL3722974 | 0.82 | PPARG (0.68) | CCR2PLA2G10F10PPARG | |
| SCHEMBL27779932 | 0.81 | CCR2 (0.57) | CCR2PLA2G10F10PPARGPLA2G2A | |
| SCHEMBL975362 | 0.81 | KMT2A (0.44) | PLA2G10F10PPARGPLA2G2APLA2G5 | |
| SCHEMBL6300893 | 0.81 | CCR2 (0.63) | CCR2F10PPARG | |
| SCHEMBL1093875 | 0.81 | CCR2 (0.69) | CCR2PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2185558-B1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF SAME | SANOFI SA (FR) | 2014-06-18 | — | — | EP | disclosed |
| EP-2235016-B1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2013-09-18 | — | — | EP | disclosed |
| CN-101977910-B | Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2013-08-07 | — | — | CN | disclosed |
| US-8420817-B2 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI (FR) | 2013-04-16 | — | — | US | disclosed |
| US-8394820-B2 | N-azabicyclic carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20120165531-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-06-28 | — | — | US | disclosed |
| US-8153796-B2 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2012-04-10 | — | — | US | disclosed |
| CN-101977910-A | Azabicyclic carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS | 2011-02-16 | — | — | CN | disclosed |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-01-13 | — | — | US | disclosed |
| EP-2235016-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-10-06 | — | — | EP | disclosed |
| US-20100173929-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2010-07-08 | — | — | US | disclosed |
| CN-101772499-A | Tricyclic N-heteroaryl-carboxamide derivatives, their preparation and their therapeutic use | SANOFIS AVENTIS | 2010-07-07 | — | — | CN | disclosed |
| EP-2185558-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF SAME | Sanofi-Aventis (FR) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009112679-A1 | AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009050348-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF SAME | SANOFIS-AVENTIS (FR) | 2009-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100173929-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | ZDHHC7, CNR2, HDAC3 | CCR2 1154/4885PLA2G10 3303/4885F10 2203/4885 |
| US-20120165531-A1 | Tricyclic N-heteroaryl-carboxamide derivatives, preparation and therapeutic use thereof | ZDHHC7, CNR2, HDAC3 | CCR2 1154/4885PLA2G10 3303/4885F10 2203/4885 |
| US-20110009444-A1 | N-AZABICYCLIC CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | XDH, NQO2, SLC28A2 | CCR2 2204/4885PLA2G10 4386/4885F10 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.